Laura Venegas, Mentor at Meta-Analysis Academy, Clinical Research Fellow at University Health Network, OncoDaily Ambassador at ASCO26, shared a post on LinkedIn:
“ASCO 2026 ADC Insights from Dr. Paolo Tarantino.
Oncology is experiencing an ‘explosion of ADCs’.
Key takeaways:
- Topoisomerase I inhibitors continue to dominate.
- However, switching the antigen target while using the same payload may not always translate into meaningful clinical advances.
Cross-resistance and overlapping toxicity remain important considerations.
A striking reminder: despite advances in linker technology, a substantial proportion of ADC payload exposure still occurs through systemic circulation, raising ongoing questions about the balance between targeted delivery and off-target toxicity.”
Other articles featuring Dr. Tarantino on OncoDaily.